Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lifirafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 11,885Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BeiGene & SpringWorks Present Clinical Data Lifirafenib, in ComBO Mirdametinib
    BeiGene & SpringWorks Present Clinical Data Lifirafenib, in ComBO Mirdametinib

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005339/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share
    SpringWorks & BeiGene Present Clinical Data on Lifirafenib, combo Mirdametinib
    SpringWorks & BeiGene Present Clinical Data on Lifirafenib, combo Mirdametinib

    17 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/17/2648395/0/en/SpringWorks-and-BeiGene-Present-Clinical-Data-on-Lifirafenib-in-combination-with-Mirdametinib-in-Patients-with-Advanced-or-Refractory-Solid-Tumors-with-MAPK-Pathway-Aberrations-at-.html

    GLOBENEWSWIRE
    17 Apr 2023
    Share Share
    SpringWorks Announces of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901
    SpringWorks Announces of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901

    06 May 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190506005105/en/SpringWorks-Therapeutics-Announces-Initiation-Phase-1b-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    06 May 2019
    Share Share
    SpringWorks names a CEO, inks a combo therapy deal with BeiGene
    SpringWorks names a CEO, inks a combo therapy deal with BeiGene

    06 Sep 2018

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/springworks-names-a-ceo-inks-a-combo-therapy-deal-beigene

    Amirah Al Idrus FIERCE BIOTECH
    06 Sep 2018
    Share Share